An open label, randomised study evaluating the efficacy and safety of Zanidatamab in combination with standard therapy versus standard therapy alone in patients with advanced HER2 positive biliary tract cancer.
Contact Information for Access
Status
ATTIVO
Objective of the study
Compare the efficacy of Zanidatamab plus Cisplatin plus Gemcitabine (CisGem) with or without a Programmed Cell Death 1 inhibitor (Programmed Cell Death 1, [PD-1]) or a Programmed Cell Death Ligand 1 (PD-L1) inhibitor (PD-1/L1 inhibitor) compared to CisGem with or without a PD-1/L1 inhibitor in participants with advanced or metastatic biliary tract cancer (BTC) that is positive for human epidermal growth factor receptor 2 (Human Epidermal Growth Factor Receptor 2, [HER2]) in participants with advanced or metastatic biliary tract cancer (
). Biliary tract cancer
Medication
Zanidatamab (Durvalumab + CisGem)
Who is eligible to participate in the study?
Patients who are 18 years of age or older and meet the study’s eligibility criteria may participate in this study.
Newly diagnosed patients.
Back to search page